Jimnez-Reina L, Caete R, de la Torre MJ, Bernal G
In a case control study, kidney length assessed by kidney ultrasound was significantly increased by approx
Orforglipron (Orfoglip), approved in 2025, is an oral GLP-1 agonist for obesity
At present, without the accurate recognition of T3cD in clinical practice and clearer resolution for differential T3cD causes, we await the continuous investigation of differential biomarkers of T2D, T3cD caused by non-PDAC diseases, and PDAC-associated diabetes in preclinical and clinical studies
This section has substances that affect potency, prostate, dementia, muscle weakness, heart health